Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 1, 2012, Pages 12-22

  Hodge, James W ^a   Sharp, Hadley J ^b,c   Gameiro, Sofia R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

abscopal; Fas; immunotherapy; modulation; radiation; vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IODINE 125; ONCOSEED; PROTEIN P53; RECOMBINANT VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRACHYTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION BEAM; RADIATION DOSE; RADIATION FIELD; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; VACCINIA VIRUS;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM REGRESSION, SPONTANEOUS; UP-REGULATION;

EID: 84856838662     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1202     Document Type: Article

References (47)

1. Blyth BJ, Sykes PJ. Radiation-induced bystander effects: What are they, and how relevant are they to human radiation exposures? Radiat Res 2011;176:139.
2. Kaminski JM, Shinohara E, Summers JB, et al. The controversial abscopal effect. Cancer Treat Rev 2005;31:159.
3. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26:234.
4. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169.
5. Robbins PF, Kantor JA, Salgaller M, et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991;51:3657.
6. Farsaci B, Sabzevari H, Higgins JP, et al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 2010;127:1603.
7. Hodge JW, Rad AN, Grosenbach DW, et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 2000;92:1228.
8. Kass E, Panicali DL, Mazzara G, et al. Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206.
9. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759.
10. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8( + ) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058.
11. Hilburger Ryan M, Abrams SI. Characterization of CD8 + cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 2001;49:603.
12. Lacabanne V, Viguier M, Guillet JG, Choppin J. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 1996;26:2635.
13. Yang JC, Perry-Lalley D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother 2000;23:177.
14. el-Shami K, Tirosh B, Bar-Haim E, et al. MHC class Irestricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 1999;29:3295.
15. Van Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996;8:355.
16. van Parijs L, Perez VL, Abbas AK. Mechanisms of peripheral T cell tolerance. Novartis Found Symp 1998;215:5.
17. Nagata S. Fas-mediated apoptosis. Adv Exp Med Biol 1996;406:119.
18. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221.
19. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469.
20. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338.
21. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class Irestricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730.
22. Rosato A, Dalla Santa S, Zoso A, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class i epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res 2003;63:2158.
23. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718.
24. Camphausen K, Moses MA, Ménard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003;63:1990.
25. Ohba K, Omagari K, Nakamura T, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998;43:575.
26. Yasuda K, Nirei T, Tsuno NH, et al. Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer. Cancer Sci 2011;102:1257.
27. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862.
28. Irvine KR, Chamberlain RS, Shulman EP, et al. Enhancing efficacy of recombinant anticancer vaccines with prime/ boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595.
29. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen responses. J Clin Oncol 2000;18:3964.
30. Chamberlain RS, Carroll MW, Bronte V, et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996;56:2832.
31. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800.
32. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328.
33. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985.
34. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006;12:1897.
35. Quarmby S, Hunter RD, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 2000;20:3375.
36. Quarmby S, Kumar P, Wang J, et al. Irradiation induces upregulation of CD31 in human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:588.
37. Ohta K, Murata H, Mori Y, et al. Remodeling of the tumor microenvironment by combined treatment with a novel radiosensitizer, {alpha}- sulfoquinovosylmonoacylglycerol ({alpha}-SQMG) and X-irradiation. Anticancer Res 2010;30:4397.
38. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002;62:1462.
39. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905.
40. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353.
41. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493.
42. Vaccine Therapy and Radiation Therapy in Treating Patients With CEA-Positive Solid Tumors That Have Metastasized to the Liver. Online document at www.clinicaltrials.gov/ct2/ show/NCT00085241 Accessed on January 11, 2010.
43. 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer. Online document at clinicaltrials.gov/ct2/ show/ NCT00450619 Accessed on January 11, 2010.
44. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379.
45. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765.
46. Hannani D, Sistigu A, Kepp O, et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011;17:351.
47. Locher C, Conforti R, Aymeric L, et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010;1209:99.